Synonyms: Factive® | LB20304 | SB 265805
gemifloxacin is an approved drug (FDA (2003))
Compound class:
Synthetic organic
Comment: Gemifloxacin is a fluoroquinolone antibacterial compound with potent activity against both Gram-negative and Gram-positive microorganisms [2-3].
|
|
No information available. |
Summary of Clinical Use ![]() |
Gemifloxacin mesylate has approval from the US FDA with a 'Boxed Warning' to highlight the risk of serious adverse reactions. It is indicated for the treatment of infections caused by susceptible strains of bacteria, including acute bacterial exacerbation of chronic bronchitis and community-acquired pneumonia (CAP), only when no other treatment options are available. The drug was marketed in the US (under the trade name Factive®) but has since been discontinued. The European Medicines Agency (EMA) withdrew approval for Factive® in 2009 [1]. |
External links ![]() |
For extended ADME data see the following: Drugs.com |